Showing results (1-10 of 10,115) with videos related to
Sort By:
Pageof 1,012
Expert Opinion on Investigational Drugs|January 6, 2010
Targeting silibinin in the antiproliferative pathwayLei Li, Jin Zeng, Ye Gao, et al.Cancer Letters|August 30, 2008
Silibinin inhibits cell growth and induces apoptosis by caspase activation, down-regulating survivin and blocking EGFR-ERK activation in renal cell carcinomaLei Li, Ye Gao, Linlin Zhang, et al.Oncology Reports|November 3, 2010
Telomerase suppression initiates PML-dependent p53 activation to inhibit bladder cancer cell growthYan Xue, Lei Li, Dong Zhang, et al.Plos One|November 24, 2011
Twisted epithelial-to-mesenchymal transition promotes progression of surviving bladder cancer T24 cells with hTERT-dysfunctionYan Xue, Lei Li, Dong Zhang, et al.Journal of Andrology|June 16, 2012
Priapism as the initial manifestation of a penile and lower limb cutaneous metastasis of prostate adenocarcinoma with low serum PSA levelDalin He, Jin Zeng, Xudong Li, et al.Disease Markers|November 18, 2020
CD82 Suppresses ADAM17-Dependent E-Cadherin Cleavage and Cell Migration in Prostate CancerZhenkun Ma, Ye Gao, Wei Liu, et al.Oncotarget|June 11, 2016
Infiltrating macrophages increase RCC epithelial mesenchymal transition (EMT) and stem cell-like populations via AKT and mTOR signalingZhao Yang, Hongjun Xie, Dalin He, et al.Molecular Medicine Reports|December 25, 2013
Urine tenascin‑C is an independent risk factor for bladder cancer patientsZhenfeng Guan, Jin Zeng, Zhiqiang Wang, et al.Oncology Reports|April 30, 2010
Silibinin reverses epithelial-to-mesenchymal transition in metastatic prostate cancer cells by targeting transcription factorsKaijie Wu, Jin Zeng, Lei Li, et al.Oncology Reports|September 2, 2015
Insulin-like growth factor binding protein-3 mediates interleukin-24-induced apoptosis through inhibition of the mTOR pathway in prostate cancerYuefeng Du, Qingzhi Long, Ying Shi, et al.Pageof 1,012